Best Price Factory Supply High Quality Huperzine a Raw Powder CAS. 120786-18-7 99% Purity

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: huperzine A
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• CAS: 120786-18-7
• Grade Standard: Medicine Grade
• Mf: C15h18n2o
• MW: 242.32
• Transport Package: Bottle, Can, Drum, Plastic Container, Vacuum Packe
• Specification: Powder
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 3001200010
• Production Capacity: 1000kilograms Per Month

Product Description

Best Price  Factory Supply High Quality huperzine A  Raw Powder   CAS.120786-18-7   99% Purity

Product name	huperzine A
CAS no.	120786-18-7
Molecular Formula	C15H18N2O
Molecular Weight	242.32
Brand Name	Senwayer

Huperzine A has been proven superior to drugs licensed for the treatment of Alzheimer's, including the leading anticholine sterase drugs physostigmine and tacrine. Huperzine A improved learning and memory in mice better than tacrine. Unlike physostigmine and tacrine, Huperzine A acts specifically on AchE in the brain rather than AchE found elsewhere in the body i.e., far less is wasted on irrelevant effects. Unlike physostigmine and tacrine, Huperzine A does not appear to bind to receptors in the central nervous system, which can cause adverse side effects. Its effects last 10 to 12 times longer than physostigmine and tacrine (up to 8 hours).

1. Huperzine A is a kind of reversible inhibitor of acetylcholinesterase, it can improve learning and memory efficiency;

2.For the treatment of myasthenia gravis, the effective rate up to 99%,and have a certain effect on age-relatedamnesia and senile dementia.

Applied in pharmaceutical field, huperzine A owning the effect of high selectivity, low toxicity and efficacy for a long time. Now it becomes international ideal drug candidate to treat Alzheimer's. It can improve myasthenia gravis, age-related memory decline and Alzheimer's disease, help young people with learning disabilities.